Empagliflozin (Jardiance): Uses, Dosing, Side Effects, and How It Compares to Other Diabetes Drugs

What Is Empagliflozin and How Does It Work?

Empagliflozin is a selective SGLT2 inhibitor that blocks glucose reabsorption in the proximal renal tubule, causing the kidneys to excrete roughly 70, 90 grams of glucose per day in urine. This glucose-wasting action lowers fasting and postprandial blood sugar without requiring insulin secretion, which matters because it carries a low intrinsic risk of hypoglycemia when used alone. The FDA first approved empagliflozin under the brand name Jardiance on August 1, 2014, for adults with type 2 diabetes mellitus as an adjunct to diet and exercise [1].

The mechanism goes beyond glucose control. By reducing glucose reabsorption, empagliflozin also lowers sodium reabsorption, which produces mild osmotic diuresis and reduces plasma volume. Researchers believe this hemodynamic effect, combined with reduced cardiac preload and afterload, partly explains the drug's cardiovascular benefits seen in outcome trials [2]. There is also evidence of direct renal tubular protection through reduced glomerular hyperfiltration.

Empagliflozin does not stimulate insulin release and does not depend on beta-cell function to work, which distinguishes it from sulfonylureas like glipizide and from insulin secretagogues more broadly [3].

FDA-Approved Indications: Beyond Blood Sugar

Jardiance now carries three distinct FDA indications, each supported by a separate large randomized trial.

Type 2 diabetes mellitus. The original 2014 approval was for glycemic management in adults. Across pooled phase III data (N=approximately 3,500), empagliflozin 10 mg reduced HbA1c by 0.66% and empagliflozin 25 mg reduced it by 0.78% versus placebo at 24 weeks [4]. Neither dose produces clinically meaningful A1C reduction below an eGFR of 30 mL/min/1.73m².

Heart failure with reduced ejection fraction (HFrEF). The EMPEROR-Reduced trial (N=3,730) randomized adults with HFrEF (ejection fraction <40%) to empagliflozin 10 mg or placebo. The primary composite outcome of CV death or hospitalization for heart failure occurred in 19.4% of the empagliflozin group versus 24.7% of placebo (hazard ratio 0.75; 95% CI 0.65, 0.87; P<0.001) [5]. The FDA added this indication in August 2021.

Chronic kidney disease (CKD). The EMPA-KIDNEY trial (N=6,609) enrolled adults with CKD across a wide eGFR range (20, 45 or 45, 90 with urinary albumin-to-creatinine ratio ≥200). Empagliflozin 10 mg reduced the risk of kidney disease progression or cardiovascular death by 28% versus placebo (HR 0.72; 95% CI 0.64, 0.82; P<0.001) [6]. This indication was approved in February 2023.

The EMPA-REG OUTCOME Trial: Cardiovascular Evidence

The EMPA-REG OUTCOME trial is the landmark study that changed prescribing patterns for type 2 diabetes globally. The trial enrolled 7,020 adults with type 2 diabetes and established cardiovascular disease, randomized to empagliflozin 10 mg, empagliflozin 25 mg, or placebo, with a median follow-up of 3.1 years [2].

Key findings:

• CV death occurred in 3.7% of the empagliflozin group versus 5.9% of placebo, a 38% relative reduction (HR 0.62; 95% CI 0.49, 0.77; P<0.001).
• Hospitalization for heart failure was reduced by 35% (HR 0.65; 95% CI 0.50, 0.85).
• All-cause mortality was reduced by 32% (HR 0.68; 95% CI 0.57, 0.82).
• The A1C difference between groups was only 0.3 to 0.5%, suggesting the mortality benefit was not driven solely by glycemic control.

As the trial authors noted in the New England Journal of Medicine: "Patients assigned to empagliflozin had a significantly lower rate of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke" [2]. The American Diabetes Association Standards of Care (2024) specifically recommend SGLT2 inhibitors with proven cardiovascular benefit as preferred agents in patients with type 2 diabetes and established atherosclerotic cardiovascular disease or heart failure [7].

Dosing and Administration

Empagliflozin is available as 10 mg and 25 mg tablets. The standard starting dose for type 2 diabetes is 10 mg once daily in the morning, taken with or without food. The dose may be increased to 25 mg once daily if tolerated and additional glycemic control is needed [1].

For heart failure and CKD, the approved dose is 10 mg once daily. Clinical trials supporting these indications used only the 10 mg dose, so the 25 mg tablet is not used for these indications [5][6].

Renal dosing adjustments. For glycemic control: empagliflozin is not recommended when eGFR is <30 mL/min/1.73m². For heart failure and CKD indications, the drug may be continued at lower eGFR levels down to an eGFR of 20 mL/min/1.73m², as studied in EMPA-KIDNEY [6]. Checking baseline eGFR before initiation is standard practice.

Missed dose. If a dose is missed, take it as soon as remembered unless it is almost time for the next dose. Do not double up.

Side Effects and Safety Considerations

Empagliflozin has a well-characterized adverse event profile after more than a decade of post-market data.

Common side effects:

• Genital mycotic infections (vulvovaginal candidiasis or balanitis) in up to 10.0% of women and 4.8% of men [1].
• Urinary tract infections in 9.3% of patients.
• Increased urination (polyuria) due to osmotic diuresis.
• Mild volume depletion, particularly in elderly patients or those on loop diuretics.

Serious but rare risks:

• Diabetic ketoacidosis (DKA). SGLT2 inhibitors can trigger euglycemic DKA, meaning blood glucose may not be markedly elevated. The FDA issued a safety communication on this risk in 2015 and recommends stopping empagliflozin at least 3 days before elective surgery or prolonged fasting [8].
• Fournier's gangrene (necrotizing fasciitis of the perineum). This is rare but has been reported across the SGLT2 inhibitor class.
• Lower-limb amputations. This signal was seen primarily with canagliflozin (CANVAS trial) and has not been statistically significant for empagliflozin in EMPA-REG OUTCOME.
• Bone fractures. No significant increase was observed in empagliflozin trials, distinguishing it from canagliflozin.

Patients should be counseled to stay well-hydrated, maintain good genital hygiene, and report any perineal pain or swelling immediately.

Empagliflozin vs. Metformin: First-Line Considerations

Metformin remains the conventional first-line agent for type 2 diabetes per most major guidelines because of its low cost, decades of safety data, and modest weight-neutral or weight-reducing profile. The ADA 2024 Standards of Care recommend metformin as an initial option for most patients with type 2 diabetes and an HbA1c within 1.5% of target [7].

Empagliflozin differs from metformin in several clinically relevant ways. Metformin lowers A1C by roughly 1.0 to 1.5% from baseline, somewhat more than empagliflozin's 0.5 to 0.8% [4][9]. Metformin is weight-neutral to mildly weight-reducing; empagliflozin produces consistent body-weight loss of 2 to 3 kg. Metformin does not carry an FDA indication for heart failure or CKD progression. Metformin's main concern is lactic acidosis in renal impairment; it is contraindicated at eGFR <30 mL/min/1.73m².

In practice, many patients with type 2 diabetes and high cardiovascular or renal risk start with or add empagliflozin early rather than waiting for metformin to fail. The 2023 ADA/EASD Consensus Report explicitly supports initiating an SGLT2 inhibitor with cardiovascular or renal benefit independent of A1C when the patient has heart failure or CKD [7].

Empagliflozin vs. Glipizide (Sulfonylurea): Hypoglycemia and Weight

Glipizide and other sulfonylureas stimulate pancreatic insulin secretion regardless of ambient glucose levels, which creates a meaningful risk of hypoglycemia (approximately 4 to 10% of patients per year) and typically causes weight gain of 2 to 4 kg [10]. The CAROLINA trial (N=6,033) directly compared linagliptin (a DPP-4 inhibitor with a similar mechanism basis to SGLT2 inhibitors) to glimepiride over 6.3 years and found significantly more hypoglycemia in the sulfonylurea arm [10]. While that trial did not include empagliflozin directly, the hypoglycemia contrast applies to SGLT2 inhibitors as a class.

Empagliflozin's glucose-wasting mechanism means hypoglycemia is uncommon as monotherapy. The drug also produces 2 to 3 kg weight loss versus the 2 to 4 kg weight gain typical with glipizide, a clinically meaningful difference for patients managing obesity alongside diabetes. Cost favors glipizide substantially. Generic glipizide costs under $10 per month, compared to $600, $700 per month for brand-name Jardiance without insurance.

Empagliflozin vs. Pioglitazone (Actos): Fluid Retention and Bone Risk

Pioglitazone (Actos) is a thiazolidinedione (TZD) that improves insulin sensitivity in peripheral tissues. It reliably lowers A1C by 0.5 to 1.4% and has modest cardiovascular benefit data in the PROactive trial (N=5,238), which showed a borderline significant reduction in the secondary composite cardiovascular endpoint [11].

The two drugs differ sharply in adverse effect profiles. Pioglitazone causes fluid retention and can precipitate or worsen heart failure, leading to an FDA black box warning against use in patients with symptomatic heart failure [12]. Empagliflozin, by contrast, reduces heart failure hospitalization and is specifically approved for this indication [5]. Pioglitazone is also associated with a 1.3, 2.1-fold increased risk of bone fractures in women and with bladder cancer (though the magnitude of the latter association remains debated) [12]. Empagliflozin has not shown a significant bone fracture signal.

On weight, pioglitazone typically causes 2 to 5 kg weight gain; empagliflozin causes 2 to 3 kg weight loss. For patients with concurrent heart failure or significant obesity, empagliflozin is generally preferred.

Empagliflozin vs. Dapagliflozin (Farxiga): Same Class, Different Trials

Dapagliflozin (Farxiga) is the closest pharmacologic cousin to empagliflozin. Both are SGLT2 inhibitors with renal glucose excretion as the primary mechanism, similar A1C-lowering capacity, and overlapping weight and blood pressure benefits. Their key differences lie in trial data and approved indications.

For cardiovascular outcomes in type 2 diabetes, DECLARE-TIMI 58 (N=17,160) tested dapagliflozin against placebo and found no significant reduction in major adverse cardiovascular events (MACE) overall (HR 0.93; 95% CI 0.84, 1.03) [13]. Empagliflozin's EMPA-REG OUTCOME showed significant MACE reduction (HR 0.86; 95% CI 0.74, 0.99), driven largely by the CV death component. This difference matters most for patients with established atherosclerotic cardiovascular disease.

For heart failure, both drugs have positive trial data. DAPA-HF (N=4,744) showed dapagliflozin reduced the primary HF composite by 26% (HR 0.74; P<0.001) [14], while EMPEROR-Reduced showed empagliflozin reduced it by 25% (HR 0.75; P<0.001) [5]. The effect sizes are nearly identical.

For CKD, DAPA-CKD (N=4,304) and EMPA-KIDNEY (N=6,609) both showed roughly 28 to 39% reductions in kidney disease progression [6][15]. EMPA-KIDNEY enrolled a broader population including patients without diabetes and those with lower eGFR.

Neither drug is clearly superior across all outcomes. Prescribers often choose based on specific indication, insurance coverage, and individual patient history.

HealthRX Clinical Decision Framework: Choosing Between Empagliflozin and Dapagliflozin

| Patient Profile | Preferred SGLT2 Inhibitor | Primary Reason | |---|---|---| | Type 2 diabetes plus established ASCVD | Empagliflozin | Significant MACE reduction in EMPA-REG OUTCOME | | Type 2 diabetes plus HFrEF | Either (both proven) | EMPEROR-Reduced and DAPA-HF show similar HR ~0.75 | | CKD without diabetes | Dapagliflozin or Empagliflozin | Both approved; EMPA-KIDNEY included non-diabetic patients | | Prior urinary tract infections | Clinical discretion | Both carry similar UTI risk; no head-to-head data | | Insurance/formulary constraint | Whichever is covered | Therapeutic interchangeability is reasonable per guidelines |

Monitoring and Contraindications

Before starting empagliflozin, clinicians should obtain a baseline eGFR, serum electrolytes, and a urinalysis. Blood pressure measurement is useful because the drug lowers systolic BP by approximately 3 to 5 mmHg through diuresis, which can be additive with antihypertensive agents [2].

Contraindications include:

• Dialysis-dependent kidney failure or eGFR <20 mL/min/1.73m² (for CKD/HF indications)
• eGFR <30 mL/min/1.73m² for glycemic indication
• Recurrent genital or urinary infections (relative contraindication; shared decision-making required)
• Type 1 diabetes (off-label use carries elevated DKA risk without established benefit)
• History of Fournier's gangrene

Patients planning elective procedures should hold empagliflozin at least 3 days before surgery and resume only after normal eating has been established, per the FDA safety communication [8].

Combination Therapy: What Pairs Well with Empagliflozin?

Empagliflozin is frequently used in combination with metformin because the mechanisms are complementary: metformin reduces hepatic glucose output and improves insulin sensitivity, while empagliflozin increases renal glucose excretion. A fixed-dose combination tablet (Synjardy, empagliflozin/metformin) is available in several strengths.

Adding empagliflozin to a GLP-1 receptor agonist such as semaglutide or liraglutide is increasingly common in patients with obesity-related type 2 diabetes and cardiovascular risk. The drugs target different mechanisms and produce additive A1C and weight reductions without increased hypoglycemia risk [7].

Combination with insulin requires monitoring for volume depletion and, rarely, for euglycemic DKA, which can be more frequent when insulin doses are reduced rapidly. Combination with sulfonylureas increases hypoglycemia risk modestly and may warrant a glipizide dose reduction.

Special Populations

Heart failure without diabetes. The EMPEROR-Reduced and EMPEROR-Preserved trials collectively support empagliflozin in HFrEF and HFpEF regardless of diabetes status [5][16]. The 2022 AHA/ACC Heart Failure Guidelines recommend SGLT2 inhibitors for patients with HFrEF to reduce hospitalization and mortality, independent of glycemic status [17].

Older adults. Volume depletion risk is higher in patients over 75. Starting at 10 mg and monitoring blood pressure and renal function at 4 to 6 weeks is prudent. The EMPA-REG OUTCOME subgroup analysis showed consistent cardiovascular benefit in patients aged 65 and older.

Pregnancy. Empagliflozin is contraindicated in the second and third trimesters. Animal studies showed adverse renal development, and the drug is not approved for gestational diabetes [1].

Chronic kidney disease without diabetes. EMPA-KIDNEY enrolled 53% of patients without a diabetes diagnosis, and the benefit on kidney disease progression was consistent across this subgroup (HR 0.73; 95% CI 0.59, 0.90) [6].

Cost, Access, and Generic Availability

Brand-name Jardiance carries a list price of approximately $600, $700 per month in the United States as of 2025. Many commercial insurance plans cover it with a tier-3 copay after prior authorization, particularly for patients with the approved cardiovascular or renal indications. Boehringer Ingelheim and Eli Lilly offer a savings card that reduces out-of-pocket cost to $10 per 30-day supply for eligible commercially insured patients.

Generic empagliflozin is not yet available in the United States as of mid-2025. Patent expiration timelines suggest first generics could enter the market between 2025 and 2028, depending on litigation outcomes. Dapagliflozin (Farxiga) faces a similar timeline.

For patients unable to afford Jardiance, dapagliflozin at comparable doses provides overlapping benefits for heart failure and CKD, and a patient assistance comparison is reasonable before abandoning the SGLT2 inhibitor class entirely.